Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q17126485> ?p ?o }
Showing triples 1 to 29 of
29
with 100 triples per page.
- Q17126485 subject Q8702202.
- Q17126485 subject Q8702225.
- Q17126485 subject Q8729038.
- Q17126485 abstract "The drug combination morphine/naltrexone (trade name Embeda) was an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain. The active ingredients were morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist. It is a schedule 2 controlled substance, and was intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated.Embeda capsules are formulated with morphine pellets and an inner core containing naltrexone. The purpose of this formulation was to prevent people from crushing the tablet for intravenous injection or intranasal ingestion. If crushed, the naltrexone would mix with the morphine and competitively antagonizes morphine's physiological effects. Ingested orally and intact, the inner core encapsulating the naltrexone is not digestible in the gastrointestinal tract.However, King Pharmaceuticals voluntarily recalled Embeda in 2011 after complaints from the FDA in regards to King Pharmaceuticals omitting information regarding the potentially fatal reaction if crushed and swallowed and also for making unsubstantiated claims regarding Embeda's reduced abuse potential.".
- Q17126485 wikiPageWikiLink Q12140.
- Q17126485 wikiPageWikiLink Q1741688.
- Q17126485 wikiPageWikiLink Q3375171.
- Q17126485 wikiPageWikiLink Q3556999.
- Q17126485 wikiPageWikiLink Q407535.
- Q17126485 wikiPageWikiLink Q409587.
- Q17126485 wikiPageWikiLink Q427523.
- Q17126485 wikiPageWikiLink Q5443593.
- Q17126485 wikiPageWikiLink Q595306.
- Q17126485 wikiPageWikiLink Q6431240.
- Q17126485 wikiPageWikiLink Q7115907.
- Q17126485 wikiPageWikiLink Q7115912.
- Q17126485 wikiPageWikiLink Q7827726.
- Q17126485 wikiPageWikiLink Q81225.
- Q17126485 wikiPageWikiLink Q8702202.
- Q17126485 wikiPageWikiLink Q8702225.
- Q17126485 wikiPageWikiLink Q8729038.
- Q17126485 wikiPageWikiLink Q908096.
- Q17126485 type ChemicalSubstance.
- Q17126485 type Drug.
- Q17126485 type ChemicalObject.
- Q17126485 type Thing.
- Q17126485 type Q8386.
- Q17126485 comment "The drug combination morphine/naltrexone (trade name Embeda) was an opioid combination pain medication developed by King Pharmaceuticals for use in moderate to severe pain. The active ingredients were morphine sulfate and naltrexone hydrochloride; morphine being an opioid receptor agonist and naltrexone an opioid receptor antagonist.".
- Q17126485 label "Morphine/naltrexone".